Cash acquisition of portfolio company Diurnal

Source: RNS
RNS Number : 6187X
IP Group PLC
30 August 2022


30 August 2022


IP Group plc - Recommended cash acquisition of portfolio company Diurnal Group plc by Neurocrine Biosciences, Inc.


IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, notes that portfolio company Diurnal Group plc ("Diurnal" or "the Company") has reached agreement with Neurocrine Biosciences, Inc. ("Neurocrine") for Diurnal to be acquired by Neurocrine for 27.5 pence in cash per share, valuing Diurnal at approximately £48.3m.

The price represents a premium of approximately 144% to the closing price per Diurnal Share of 11.25 pence on 26 August 2022 and 151% to the volume weighted average closing price of 10.93 pence per Diurnal share for the three months ended on the latest practicable date.

As a result, IP Group, which has a holding of 29.4% in Diurnal, will receive approximately £14m in cash. The acquisition is conditional on, amongst other things, the approval of Diurnal shareholders.

For more information, please contact:


IP Group plc

Liz Vaughan-Adams, Communications           

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995


Notes for editors


About IP Group


IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.


For more information, please visit our website at


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.